In October 2025, DiaUnion joined a forward-looking seminar in Stockholm to discuss how early detection of T1D can be integrated into Swedish healthcare – and how it aligns with national strategies for precision medicine.
The event brought together voices from across the healthcare system – clinicians, researchers, patient organisations, policymakers, and life science stakeholders – to discuss how we move towards implementation.
Daniel Agardh was part of the programme and joined a panel session where practical insights from current screening programmes were shared – and where the conversation focused on what it will take to implement future early detection in a way that is evidence-based, ethical, and effective.
The seminar also highlighted the role of precision medicine in national life science strategies – in both Sweden and Denmark. As Pedro F. Teixeira from Diamyd pointed out in his presentation, this is an increasingly important priority in both countries’ visions for the future of healthcare.
The event was organised by Leading Health Care Foundation within the ASSET network and supported by Diamyd Medical in collaboration with Sanofi and DiaUnion.
A warm thank you to all involved – we look forward to the continued dialogue and next steps when it comes to bringing early detection of T1D to more people in Sweden and beyond.
